Vertex Pharma, UnitedHealth Group Outshine Healthcare Sector Amid Regulatory Risks

The healthcare industry has been booming lately, with stocks returning 46.9% over the past six months, outperforming the S&P 500 by 25.5 percentage points.

Despite its growth, investors should be cautious as the sector is heavily regulated and subject to changing rules that can negatively impact businesses.

Two stocks stand out for their resilience: Vertex Pharmaceuticals (VRTX) and UnitedHealth Group (UNH).

Vertex Pharmaceuticals has achieved 13.5% annual revenue growth over the last five years, beating the sector average and underscoring the unique value of its offerings.

The company's adjusted operating profits have increased over the last two years as it gained leverage on fixed costs and became more efficient.

Vertex Pharmaceuticals trades at $523.65 per share, with a valuation ratio of 40.4x forward P/E.

UnitedHealth Group, on the other hand, has an unparalleled scale of $450.1 billion in revenue, enabling it to spread administrative costs across its large membership base.

The company's market-beating returns on capital illustrate management's knack for investing in profitable ventures.

However, The Pennant Group (PNTG) falls short due to a smaller revenue base of $1.09 billion and a poor free cash flow margin of 2.4% over the last five years.